Breaking News
Investing Pro 0
Donate to earthquake relief efforts in Turkey and Syria Donate

Two Appealing Biotech Stocks For Two Distinct Investors

By MarketBeat.com (Chris Markoch )Stock MarketsAug 09, 2022 01:24AM ET
www.investing.com/analysis/two-appealing-biotech-stocks-for-two-distinct-investors-200628237
Two Appealing Biotech Stocks For Two Distinct Investors
By MarketBeat.com (Chris Markoch )   |  Aug 09, 2022 01:24AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
AMGN
+0.06%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
INO
+1.09%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ABBV
+0.08%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MRNA
+0.46%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
  • Amgen (NASDAQ:AMGN) is a proven performer with an expansive pipeline
  • Inovio Pharmaceuticals (NASDAQ:INO) Investment in the future of medicine
  • Investing in biotech companies also carries substantial risk

The appeal of investing in biotechnology (i.e., biotech) companies is understandable. When one of these companies brings a drug or therapeutic treatment to market, it has an immediate positive impact on revenue and earnings. And that combination begins a cycle that includes analyst upgrades and stock price growth.

There are other benefits to investing in biotech companies. For example, once these products hit the market, the company generally has patent protection. This means that it can keep out generic competition for several years. In the best-case scenario, the revenue and earnings from these successful products is the fuel that allows the company to bring other products to market.

This was the case with AbbVie (NYSE:ABBV), which brought the rheumatoid arthritis treatment Humira to market. Even as the patent protection on Humira is expiring, the company is beginning to see revenue growth from new products such as Skyrizi and Rinvoq.

Plus, the process of bringing their drugs to market is extensive, creating a wide moat. That was the case for a company like Moderna (NASDAQ:MRNA). The company saw its stock jump when its COVID-19 vaccine candidate received an Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration in 2020.

However, investing in biotech companies also carries substantial risk. One of the largest risks is that a company may never bring a product to market. Moving a drug/therapeutic candidate through the clinical trial stage is a lengthy, expensive process. And there’s no guarantee that companies will be successful.

This article highlights two biotech companies that offer different opportunities depending on your investment style.

A Proven Performer with an Expansive Pipeline

If you’re an investor looking for solid defensive stocks with the chance for a bit of growth, Amgen Inc (NASDAQ:AMGN) is one for your watch list. The company has several products already on the market. The two that may carry the most name recognition are Enbril and Otezla, used to treat inflammatory diseases. The company has a deep pipeline of products in various clinical trial stages.

AMGN stock trades at a price-to-earnings (P/E) ratio of over 20x earnings. That's slightly above the sector average of 17x earnings. However, the company is expected to post single-digit revenue and earnings growth over the next five years so the P/E ratio doesn’t seem out of line.

Plus, investors have the benefit of a dividend that currently pays out $7.76 per share on an annual basis. That factors to a current dividend ratio of 3.15%. And the dividend is supported by strong free cash flow, which supports the idea that Amgen is likely to continue to increase its dividend, which it has done in the last 11 years.

A Speculative Investment in the Future of Medicine

In contrast to Amgen, Inovio Pharmaceuticals (NASDAQ:INO) does not yet have a product on the market. And although it has several products in clinical trials, the company is several years away from generating revenue, let alone becoming a profitable company.

And that is reflected in the INO stock price. The company got a boost during the pandemic (more on that in a second) but has largely been trading in the penny stock range (i.e., below $5 per share). And the stock is down over 50% in 2022, lagging the broader market.

That being said, Inovio is about the future. The company is working to develop a portfolio of DNA-based therapeutic treatments. This must be described accurately, so I’d encourage you to hear about this straight from the company should you be interested in investing. However, some easy-to-understand benefits are the speed at which medicines could be designed and manufactured and the ability to ship and store them at room temperatures.

As mentioned above, the company was part of the race to develop a Covid-19 vaccine. The company is still trying to bring its candidate, INO-4800 to market. And the company recently undertook several cost-cutting measures to remain funded into 2024. However, that also implies that it could be years away from generating meaningful revenue and even further away from generating a profit. But if you have some speculative money with time on your side, INO stock may merit a closer look.

Original Post

Two Appealing Biotech Stocks For Two Distinct Investors
 

Related Articles

Jani Ziedins
How Smart Money Is Trading S&P 500 By Jani Ziedins - Feb 08, 2023 5

Tuesday was a whipsaw session for the S&P 500, but by the time dust settled, the index powered 1.3% higher, ending a two-day losing streak. The day’s big headline was public...

Two Appealing Biotech Stocks For Two Distinct Investors

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email